Biopharmaceutical CMO Market is expected to increase at a compound annual growth rate (CAGR) of 18.5% from 2025 to 2035
The biopharmaceutical CMO market is anticipated to reach USD 56.8
billion by 2035 from USD 17.1 billion in 2024, at a CAGR of 18.5% during the
forecast period 2025-2035.
An organization
that provides manufacturing solutions to biopharmaceutical companies under a
fee-based agreement is known as a biopharmaceutical contact manufacturing
organization (CMO) market. From early development to commercial production,
these CMOs work on most phases of the drug production process. It plays a
crucial position in the design of the pharmaceutical supply chain since
contract manufacturing enables biotechnology businesses, especially those that
are just getting started and expanding, to obtain the best manufacturing
facilities without having to make significant financial investments.
Request For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/biopharmaceutical-cmo-market
Growth
Drivers:
Due to the
growing demand for biologic and biosimilar drugs, the worldwide
biopharmaceutical CMO market is expanding quickly. For many chronic diseases,
including diabetes, autoimmune diseases, and cancer, biologics—which include
recombinant proteins, monoclonal antibodies, and vaccines—have become the gold
standard of care. Biosimilars, which are biologic medications that are
identical as authorized biologics but typically cost less, are another type
that is gaining popularity.
Another
important driver propelling the biopharmaceutical CMO market is a rise in the
total amount of money pharmaceutical and biotech companies spend on research
and development. The International Federation of Pharmaceutical Manufacturers
and Associations (IFPMA), for example, estimates that the research-based
biopharmaceutical industry spent USD 196 billion on biopharmaceutical R&D
worldwide in 2023. The expansion of biopharmaceutical CMO is mostly driven by
the transition towards biologic pharmaceuticals, as most of these businesses
frequently look for clinical trial providers and third-party manufacturers in
the early stages of production.
Biopharmaceutical
CMO Segmentation:
By
Product:
· Biologics
o Vaccines
o Recombinant
Proteins
o Antisense
RNAi, & Molecular Therapies
o Gene
Therapies
o Monoclonal
Antibodies (MABs)
o Others
· Biosimilars
By
Source:
· Mammalian
· Non-Mammalian
By
Service:
· Manufacturing
o Upstream
Processing
o Downstream
Processing
· Fill
& Finish Operations
· Packaging
· Analytical
& AC Studies
· Others
By
Region:
· North
America
· Europe
· Asia
Pacific
· Latin
America
· Middle
East and Africa
Key
Companies in Biopharmaceutical CMO Market:
The research
report offers a competitive analysis of prominent companies operating in the
global biopharmaceutical CMO market. Some of the leading players profiled in
the market research report include:
· Thermo
Fisher Scientific, Inc.
· Lonza
· Samsung
Biologics
· Catalent,
Inc.
· Cambrex
Corporation
· Recipharm
AB
· WuXi
Biologics
· FUJIFILM
Diosynth Biotechnologies
· Siegfried
Holding AG
· Laboratory
Corporation of America® Holdings
· Other
Player’s
For More Information about this Report @
https://www.xresearch.biz/shop/biopharmaceutical-cmo-market
About Us: -
xResearch is a market research and consulting
organization that uses unique data, expert analysis, and new technologies to
create trusted intelligence on industries. Our research is focused on
delivering an informed and impartial view on essential market data of industry,
and it is primarily driven by an in-depth study covering the following
parameters: Market Sizing and Forecasting, Market Segmentation, Competitive
Analysis, Strategic Assessment and Business Modelling.
Contact:
Company Name: xResearch
Contact Person: James Lin
Email: sales@xresearch.biz
Phone: +1 718-619-8140
Websites: https://www.xresearch.biz/

Comments
Post a Comment